Oncology & Cancer

Transfusion dose density affects myelodysplastic syndrome survival

(HealthDay)—Transfusion dose density is an independent prognostic factor for progression-free survival (PFS) in patients with myelodysplastic syndromes treated with red blood cell transfusions (RBCTs), according to a study ...

Oncology & Cancer

Population mortality affects long-term follow-up of AlloHCT

(HealthDay)—For older patients undergoing allogeneic hematopoietic cell transplantation (alloHCT), a considerable part of total nonrelapse mortality (NRM) is attributable to population mortality, according to a study recently ...

Oncology & Cancer

Cumbersome blood cancer treatment can be postponed

It's possible to postpone the introduction of blood transfusions for an average of 17 months for patients with the low-risk variant of MDS blood cancer, provided they are given erythropoiesis-stimulating agents (ESA), which ...

Oncology & Cancer

Response to lenalidomide often suboptimal in MDS/MPN-RS-T

(HealthDay)—Lenalidomide produces hematologic responses in myelodysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN) with ring sideroblasts (RS) and thrombocytosis (MDS/MPN-RS-T), although these responses are often ...

Oncology & Cancer

Mysterious gene transcripts after cancer therapy

Tumor suppressor genes protect cells from malignant transformation. If they are turned off as a result of chemical modifications in DNA, called epigenetic labels, this contributes to the development of cancer. As opposed ...

page 1 from 2